Document Detail


The role of low-molecular-weight heparin in cardiovascular diseases.
MedLine Citation:
PMID:  12411975     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Unfractionated heparin continues to have important limitations in clinical practice. It has an inconsistent anticoagulant effect, needs frequent monitoring, and is inactivated by several plasma proteins. Low-molecular-weight heparins have a more predictable anticoagulant effect than unfractionated heparin, are easier to administer, and may not require monitoring. The anticoagulation effect of low-molecular-weight heparins is caused by a combination of inhibition of thrombin generation and inhibition of thrombin activity. Low-molecular-weight heparins have now been evaluated for a number of cardiovascular conditions and have been found to be safe and effective. We review and summarize the existing data regarding the use of low-molecular-weight heparins in cardiovascular diseases, including venous thromboembolism, percutaneous coronary interventions, and acute coronary syndromes such as ST-segment elevation myocardial infarction.
Authors:
Debabrata Mukherjee; Eric J Topol
Related Documents :
18473865 - Factor xa inactivation in acute coronary syndrome.
12215055 - Management of patients with acute coronary syndromes: what is the clinical role of dire...
11350475 - Risk factors for fatal myocardial infarction after coronary bypass graft surgery.
15976785 - Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients wi...
8800135 - "hibernating" myocardium: asleep or part dead?
8261235 - An additional marker for familial hypertrophic cardiomyopathy?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Progress in cardiovascular diseases     Volume:  45     ISSN:  0033-0620     ISO Abbreviation:  Prog Cardiovasc Dis     Publication Date:    2002 Sep-Oct
Date Detail:
Created Date:  2002-11-04     Completed Date:  2002-12-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376442     Medline TA:  Prog Cardiovasc Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  139-56     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2002, Elsevier Science (USA). All rights reserved.
Affiliation:
Division of Cardiology, University of Michigan, Ann Arbor, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angina, Unstable / drug therapy
Cardiovascular Diseases / drug therapy*
Clinical Trials as Topic
Drug Therapy, Combination
Fibrinolytic Agents / therapeutic use*
Heart Catheterization / methods
Heparin, Low-Molecular-Weight / therapeutic use*
Humans
Integrin beta3 / therapeutic use
Myocardial Infarction / drug therapy
Platelet Membrane Glycoprotein IIb / therapeutic use
Thromboembolism / drug therapy
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 0/Integrin beta3; 0/Platelet Membrane Glycoprotein IIb

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Eisenmenger's syndrome: current management.
Next Document:  Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of ...